My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 390

    1.

    Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group.

    Graham NM, Hoover DR, Park LP, Stein DS, Phair JP, Mellors JW, Detels R, Saah AJ.

    Ann Intern Med. 1996 Jun 15;124(12):1031-8.PMID: 8633816 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study.

    Stein DS, Graham NM, Park LP, Hoover DR, Phair JP, Detels R, Ho M, Saah AJ.

    Ann Intern Med. 1994 Jul 15;121(2):100-8.PMID: 8017721 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.

    Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, Markowitz N, Reves R, Loveless MO, Crane L, Thompson M, Abrams D.

    N Engl J Med. 1996 Oct 10;335(15):1099-106.PMID: 8813040 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.

    [No authors listed]

    Lancet. 1999 Jun 12;353(9169):2014-25.PMID: 10376616 [PubMed - indexed for MEDLINE]Related articles

    5.

    A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

    Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC.

    N Engl J Med. 1996 Oct 10;335(15):1081-90.PMID: 8813038 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.

    Moyle GJ, Bouza E, Antunes F, Smith D, Harris R, Warburg M, Walker M.

    Antivir Ther. 1997 Dec;2(4):229-36.PMID: 11327442 [PubMed - indexed for MEDLINE]Related articles

    7.

    Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.

    [No authors listed]

    Lancet. 1996 Aug 3;348(9023):283-91. Erratum in: Lancet 1996 Sep 21;348(9030):834. PMID: 8709686 [PubMed - indexed for MEDLINE]Related articles

    8.

    A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.

    Henry K, Erice A, Tierney C, Balfour HH Jr, Fischl MA, Kmack A, Liou SH, Kenton A, Hirsch MS, Phair J, Martinez A, Kahn JO.

    J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):339-49.PMID: 9833742 [PubMed - indexed for MEDLINE]Related articles

    9.

    Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study.

    van Leeuwen R, Bonsel GJ, Reiss P, Danner SA, Lange JM.

    J Infect Dis. 1997 Jun;175(6):1344-51.PMID: 9180173 [PubMed - indexed for MEDLINE]Related articles

    10.

    Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

    Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H.

    JAMA. 1996 Jul 10;276(2):118-25.PMID: 8656503 [PubMed - indexed for MEDLINE]Related articles

    11.

    Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.

    Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF.

    J Infect Dis. 1996 Jun;173(6):1354-66.PMID: 8648207 [PubMed - indexed for MEDLINE]Related articles

    12.

    Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

    Staszewski S, Loveday C, Picazo JJ, Dellarnonica P, Skinhøj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L, McDade H.

    JAMA. 1996 Jul 10;276(2):111-7.PMID: 8656502 [PubMed - indexed for MEDLINE]Related articles

    13.

    Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

    Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP.

    JAMA. 1998 Nov 4;280(17):1497-503.PMID: 9809730 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.

    Montaner JS, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg MA.

    Ann Intern Med. 1995 Oct 15;123(8):561-71.PMID: 7677296 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.

    Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, Allan JD, Goldsmith JC, Powderly WG.

    Ann Intern Med. 1995 Jan 1;122(1):24-32.PMID: 7985892 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.

    [No authors listed]

    Lancet. 1997 May 17;349(9063):1413-21.PMID: 9164314 [PubMed - indexed for MEDLINE]Related articles

    17.

    Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.

    D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD.

    Ann Intern Med. 1995 Mar 15;122(6):401-8.PMID: 7856987 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.

    Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J Jr, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkle L.

    Ann Intern Med. 1997 Mar 1;126(5):355-63.PMID: 9054279 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

    García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

    AIDS. 1999 Dec 3;13(17):2377-88.PMID: 10597779 [PubMed - indexed for MEDLINE]Related articles

    20.

    Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.

    Gatell JM, González-Lahoz J, Clotet B, Antunes F, Kasparova L, Gil-Aguado A, Saballs P, Santamaria JM, Podzamczer D, Miro JM, Jou A, Verdejo J, Doroana M, Thomis J.

    J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul;12(3):249-58.PMID: 8673528 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity